315 related articles for article (PubMed ID: 1309056)
1. Remaining perspectives of mutant and chimeric plasminogen activators.
Lijnen HR; Collen D
Ann N Y Acad Sci; 1992 Dec; 667():357-64. PubMed ID: 1309056
[TBL] [Abstract][Full Text] [Related]
2. Hybrid molecules: insights into plasminogen activator function.
Runge MS; Bode C; Haber E; Quertermous T
Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
[TBL] [Abstract][Full Text] [Related]
3. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons.
Runge MS; Harker LA; Bode C; Ruef J; Kelly AB; Marzec UM; Allen E; Caban R; Shaw SY; Haber E; Hanson SR
Circulation; 1996 Sep; 94(6):1412-22. PubMed ID: 8823001
[TBL] [Abstract][Full Text] [Related]
4. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
5. Newer thrombolytic drugs for acute myocardial infarction.
Reddy DS
Indian J Exp Biol; 1998 Jan; 36(1):1-15. PubMed ID: 9536645
[TBL] [Abstract][Full Text] [Related]
6. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
[TBL] [Abstract][Full Text] [Related]
7. Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase.
Hagemeyer CE; Tomic I; Weirich U; Graeber J; Nordt T; Runge MS; Bode C; Peter K
J Thromb Haemost; 2004 May; 2(5):797-803. PubMed ID: 15099287
[TBL] [Abstract][Full Text] [Related]
8. A recombinant antibody-targeted plasminogen activator with high affinity for activated platelets increases thrombolytic potency in vitro and in vivo.
Wan H; Liu Z; Xia X; Gu J; Wang B; Liu X; Zhu M; Li P; Ruan C
Thromb Res; 2000 Feb; 97(3):133-41. PubMed ID: 10680644
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.
Holvoet P; Laroche Y; Stassen JM; Lijnen HR; Van Hoef B; De Cock F; Van Houtven A; Gansemans Y; Matthyssens G; Collen D
Blood; 1993 Feb; 81(3):696-703. PubMed ID: 8427962
[TBL] [Abstract][Full Text] [Related]
10. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
Collen D; Dewerchin M; Rapold HJ; Lijnen HR; Stassen JM
Circulation; 1990 Nov; 82(5):1744-53. PubMed ID: 2121385
[TBL] [Abstract][Full Text] [Related]
11. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
Dewerchin M; Lijnen HR; Stassen JM; De Cock F; Quertermous T; Ginsberg MH; Plow EF; Collen D
Blood; 1991 Aug; 78(4):1005-18. PubMed ID: 1831057
[TBL] [Abstract][Full Text] [Related]
12. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
[TBL] [Abstract][Full Text] [Related]
13. Thrombolytic agents in development.
Verstraete M; Lijnen HR; Collen D
Drugs; 1995 Jul; 50(1):29-42. PubMed ID: 7588087
[TBL] [Abstract][Full Text] [Related]
14. New thrombolytic drugs.
Thomson A
Aust N Z J Med; 1999 Jun; 29(3):433-5. PubMed ID: 10868516
[TBL] [Abstract][Full Text] [Related]
15. Construction and characterization of a recombinant chimeric plasminogen activator consisting of a fibrin peptide and a low molecular mass single-chain urokinase.
Jiao J; Yu M; Ru B
Biochimie; 2001; 83(11-12):1049-55. PubMed ID: 11879733
[TBL] [Abstract][Full Text] [Related]
16. Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
Holvoet P; Laroche Y; Lijnen HR; Van Hoef B; Brouwers E; De Cock F; Lauwereys M; Gansemans Y; Collen D
Eur J Biochem; 1992 Dec; 210(3):945-52. PubMed ID: 1483477
[TBL] [Abstract][Full Text] [Related]
17. Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
Holvoet P; Dewerchin M; Stassen JM; Lijnen HR; Tollenaere T; Gaffney PJ; Collen D
Circulation; 1993 Mar; 87(3):1007-16. PubMed ID: 8443877
[TBL] [Abstract][Full Text] [Related]
18. [Plasminogen activators and thrombolytic therapy].
Taran LD
Biomed Khim; 2005; 51(3):248-62. PubMed ID: 16104388
[TBL] [Abstract][Full Text] [Related]
19. Tissue-type plasminogen activator (tPA) interacts with urokinase-type plasminogen activator (uPA) via tPA's lysine binding site. An explanation of the poor fibrin affinity of recombinant tPA/uPA chimeric molecules.
Novokhatny V; Medved L; Lijnen HR; Ingham K
J Biol Chem; 1995 Apr; 270(15):8680-5. PubMed ID: 7721771
[TBL] [Abstract][Full Text] [Related]
20. Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets.
Wang X; Palasubramaniam J; Gkanatsas Y; Hohmann JD; Westein E; Kanojia R; Alt K; Huang D; Jia F; Ahrens I; Medcalf RL; Peter K; Hagemeyer CE
Circ Res; 2014 Mar; 114(7):1083-93. PubMed ID: 24508759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
